

Franco E Odicino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1854511/publications.pdf>

Version: 2024-02-01

108
papers

7,413
citations

76326

40
h-index

54911

84
g-index

110
all docs

110
docs citations

110
times ranked

8423
citing authors

#	ARTICLE	IF	CITATIONS
1	Chorionicity, birth weight discordance and neonatal morbidity in uncomplicated twin pregnancies delivered from 36 weeks. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2022, 271, 214-218.	1.1	0
2	VEGF-D Serum Level as a Potential Predictor of Lymph Node Metastasis and Prognosis in Vulvar Squamous Cell Carcinoma Patients. <i>Frontiers in Oncology</i> , 2022, 12, 818613.	2.8	1
3	Ultrasound and magnetic resonance imaging in the diagnosis of clinically significant placenta accreta spectrum disorders. <i>Journal of Perinatal Medicine</i> , 2022, 50, 277-285.	1.4	6
4	Management of Large Pediatric and Adolescent Ovarian Neoplasms with a Leak-Proof Extracorporeal Drainage Technique: Our Experience Using a Hybrid Minimally Invasive Approach. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2021, 34, 394-399.	0.7	3
5	Clear cell degeneration associated with endometriosis of abdominal wall after cesarean section: A case report and systematic review of literature. <i>Journal of Obstetrics and Gynaecology Research</i> , 2021, 47, 1243-1252.	1.3	3
6	Current Treatment Options for Cervical Leiomyomas: A Systematic Review of Literature. <i>Medicina (Lithuania)</i> , 2021, 57, 92.	2.0	12
7	The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell Features. <i>Cancers</i> , 2021, 13, 906.	3.7	6
8	Integrated mutational landscape analysis of uterine leiomyosarcomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	7.1	48
9	Pre-eclampsia and late fetal growth restriction. <i>Minerva Obstetrics and Gynecology</i> , 2021, 73, 435-441.	1.0	3
10	Risk Assessment in Solitary Fibrous Tumor of the Uterine Corpus: Report of a Case and Systematic Review of the Literature. <i>International Journal of Surgical Pathology</i> , 2021, , 106689692110257.	0.8	9
11	Comprehensive Profiling of Hypoxia-Related miRNAs Identifies miR-23a-3p Overexpression as a Marker of Platinum Resistance and Poor Prognosis in High-Grade Serous Ovarian Cancer. <i>Cancers</i> , 2021, 13, 3358.	3.7	9
12	PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicine. , 2021, 9, e002179.		6
13	Organization of an obstetrics unit during the COVID-19 pandemic: a short literature review. <i>SeÄenovskij Vestnik</i> , 2021, 12, 12-19.	0.4	2
14	Laparoscopic Access with Optical Gasless Trocar: A Single-center Experience of 7431 Procedures. <i>Journal of Minimally Invasive Gynecology</i> , 2020, 27, 535-540.	0.6	5
15	Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' Italiana di Ginecologia e Obstetrica). <i>Journal of Obstetrics and Gynaecology Research</i> , 2020, 46, 1243-1252.	2.8	9
16	Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1287.	2.8	9
17	Endometrial Carcinomas with Intestinal-Type Metaplasia/Differentiation: Does Mismatch Repair System Defects Matter? Case Report and Systematic Review of the Literature. <i>Journal of Clinical Medicine</i> , 2020, 9, 2552.	2.4	24
18	Extra-abdominal ovarian cancer presenting with breast metastases at diagnosis: Case report and literature review. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2020, 255, 211-221.	1.1	1

#	ARTICLE	IF	CITATIONS
19	Pre-treatment Serum HE4 Level as a Novel Independent Prognostic Biomarker for Uterine Cervical Carcinoma Patients. <i>Frontiers in Oncology</i> , 2020, 10, 584022.	2.8	6
20	Validation of an enhanced recovery after surgery protocol in gynecologic surgery: an Italian randomized study. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 543.e1-543.e14.	1.3	41
21	Expression profiles of PRKG1, SDF2L1 and PPP1R12A are predictive and prognostic factors for therapy response and survival in high-grade serous ovarian cancer. <i>International Journal of Cancer</i> , 2020, 147, 565-574.	5.1	15
22	Impact of endometrial sampling technique and biopsy volume on the diagnostic accuracy of endometrial cancer. <i>Translational Cancer Research</i> , 2020, 9, 7697-7705.	1.0	8
23	Survival implication of lymphadenectomy in patients surgically treated for apparent early-stage uterine serous carcinoma. <i>Journal of Gynecologic Oncology</i> , 2020, 31, e64.	2.2	30
24	Adnexal torsion with normal ovary in the third trimester of a twin pregnancy: Case report and literature review. <i>Journal of Obstetrics and Gynaecology Research</i> , 2019, 45, 226-229.	1.3	4
25	Multivariate analysis of prognostic factors in primary squamous cell vulvar cancer: The role of perineural invasion in recurrence and survival. <i>European Journal of Surgical Oncology</i> , 2019, 45, 2115-2119.	1.0	27
26	Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 22730-22736.	7.1	52
27	FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients. <i>British Journal of Cancer</i> , 2019, 121, 584-592.	6.4	30
28	Role of HPV DNA and HPV mRNA and cytology in the follow-up of women treated for cervical dysplasia. <i>Apmis</i> , 2019, 127, 196-201.	2.0	5
29	Opportunistic salpingectomy during postpartum contraception procedures at elective and unscheduled cesarean delivery. <i>Contraception</i> , 2019, 99, 373-376.	1.5	17
30	Laparoscopic management of a large urethral leiomyoma. <i>International Urogynecology Journal</i> , 2019, 30, 1211-1213.	1.4	10
31	Transcriptional Characterization of Stage I Epithelial Ovarian Cancer: A Multicentric Study. <i>Cells</i> , 2019, 8, 1554.	4.1	9
32	Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 619-624.	7.1	49
33	Parametrial endometriosis with ureteral involvement: A case report of a conservative approach without ureteral resection. <i>Journal of Endometriosis and Pelvic Pain Disorders</i> , 2018, 10, 222-223.	0.5	4
34	Claudin3 is localized outside the tight junctions in human carcinomas. <i>Oncotarget</i> , 2018, 9, 18446-18453.	1.8	15
35	FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients. <i>Journal of Experimental and Clinical Cancer Research</i> , 2017, 36, 63.	8.6	53
36	Polymerase Îµ (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro. <i>Gynecologic Oncology</i> , 2017, 144, 146-152.	1.4	55

#	ARTICLE	IF	CITATIONS
37	Circulating miRNA landscape identifies miR-1246 as promising diagnostic biomarker in high-grade serous ovarian carcinoma: A validation across two independent cohorts. <i>Cancer Letters</i> , 2017, 388, 320-327.	7.2	73
38	RERT: A Novel Regression Tree Approach to Predict Extrauterine Disease in Endometrial Carcinoma Patients. <i>Scientific Reports</i> , 2017, 7, 10528.	3.3	19
39	MAL gene overexpression as a marker of high-grade serous ovarian carcinoma stem-like cells that predicts chemoresistance and poor prognosis. <i>BMC Cancer</i> , 2017, 17, 366.	2.6	16
40	Kinase-driven metabolic signalling as a predictor of response to carboplatin+paclitaxel adjuvant treatment in advanced ovarian cancers. <i>British Journal of Cancer</i> , 2017, 117, 494-502.	6.4	10
41	lncRNAs as Novel Indicators of Patients' Prognosis in Stage I Epithelial Ovarian Cancer: A Retrospective and Multicentric Study. <i>Clinical Cancer Research</i> , 2017, 23, 2356-2366.	7.0	57
42	Identification of stably expressed reference small non-coding RNA for microRNA quantification in high-grade serous ovarian carcinoma tissues. <i>Journal of Cellular and Molecular Medicine</i> , 2016, 20, 2341-2348.	3.6	50
43	Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2016, 469, 61-69.	2.8	23
44	Mutational landscape of uterine and ovarian carcinosarcomas implicates histone genes in epithelial-mesenchymal transition. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 12238-12243.	7.1	181
45	The HIV-protease inhibitor saquinavir reduces proliferation, invasion and clonogenicity in cervical cancer cell lines. <i>Oncology Letters</i> , 2016, 12, 2493-2500.	1.8	14
46	HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study. <i>Gynecologic Oncology</i> , 2016, 141, 303-311.	1.4	87
47	Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum. <i>Obstetrics and Gynecology</i> , 2015, 126, 171-174.	2.4	87
48	FIGO's staging classification for cancer of the ovary, fallopian tube, and peritoneum: abridged republication. <i>Journal of Gynecologic Oncology</i> , 2015, 26, 87.	2.2	238
49	Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug delivery. <i>Oncotarget</i> , 2015, 6, 34617-34628.	1.8	15
50	Management of endometrial cancer in Italy: A national survey endorsed by the Italian Society of Gynecologic Oncology. <i>International Journal of Surgery</i> , 2014, 12, 1038-1044.	2.7	15
51	Protein network mapping of glucose metabolism in ovarian cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 5550-5550.	1.6	0
52	Human epididymis protein 4 as a serum marker for diagnosis of endometrial carcinoma and prediction of clinical outcome. <i>Clinical Chemistry and Laboratory Medicine</i> , 2012, 50, 2189-2198.	2.3	72
53	Serum Human Epididymis Protein 4 and Risk for Ovarian Malignancy Algorithm as New Diagnostic and Prognostic Tools for Epithelial Ovarian Cancer Management. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2011, 20, 2496-2506.	2.5	112
54	Diagnostic and prognostic impact of serum HE4 detection in endometrial carcinoma patients. <i>British Journal of Cancer</i> , 2011, 104, 1418-1425.	6.4	134

#	ARTICLE	IF	CITATIONS
55	Investigation of the Ovarian and Prostate Cancer Peptidome for Candidate Early Detection Markers Using a Novel Nanoparticle Biomarker Capture Technology. <i>AAPS Journal</i> , 2010, 12, 504-518.	4.4	51
56	Trop-2 overexpression as an independent marker for poor overall survival in ovarian carcinoma patients. <i>European Journal of Cancer</i> , 2010, 46, 944-953.	2.8	94
57	Abstract 4584: Verification of ovarian cancer biomarker candidates by nanoparticle-capture MRM. , 2010, , .		0
58	Mammaglobin B is an independent prognostic marker in epithelial ovarian cancer and its expression is associated with reduced risk of disease recurrence. <i>BMC Cancer</i> , 2009, 9, 253.	2.6	19
59	Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: Results from the SOCRATES retrospective study. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 71, 233-241.	4.4	32
60	Revised FIGO staging for carcinoma of the cervix. <i>International Journal of Gynecology and Obstetrics</i> , 2009, 105, 107-108.	2.3	582
61	Clinical Approach to Adnexal Disease. , 2009, , 411-417.		0
62	Trefoil factor 3: a novel serum marker identified by gene expression profiling in high-grade endometrial carcinomas. <i>British Journal of Cancer</i> , 2008, 99, 768-773.	6.4	40
63	HER-2/ <i>neu</i> overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence <i>in situ</i> hybridization. <i>International Journal of Gynecological Cancer</i> , 2008, 18, 14-21.	2.5	70
64	Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. <i>BMC Cancer</i> , 2008, 8, 252.	2.6	44
65	History of the FIGO cancer staging system. <i>International Journal of Gynecology and Obstetrics</i> , 2008, 101, 205-210.	2.3	145
66	Which second-line treatment regimen should be used following relapse of platinum-sensitive ovarian cancer?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 340-341.	4.3	0
67	Results of the 2006 Innsbruck International Consensus Conference on intraperitoneal chemotherapy in patients with ovarian cancer. <i>Cancer</i> , 2007, 109, 645-649.	4.1	28
68	New development of the FIGO staging system. <i>Gynecologic Oncology</i> , 2007, 107, S8-S9.	1.4	10
69	Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. <i>Gynecologic Oncology</i> , 2007, 107, S241-S247.	1.4	92
70	Carcinoma of the Vulva. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 95, S7-S27.	2.3	123
71	Carcinoma of the Vagina. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 95, S29-S42.	2.3	69
72	Carcinoma of the Corpus Uteri. <i>International Journal of Gynecology and Obstetrics</i> , 2006, 95, S105-43.	2.3	790

#	ARTICLE	IF	CITATIONS
73	Carcinoma of the Fallopian Tube. International Journal of Gynecology and Obstetrics, 2006, 95, S145-S160.	2.3	52
74	Carcinoma of the Ovary. International Journal of Gynecology and Obstetrics, 2006, 95, S161-92.	2.3	950
75	Gestational Trophoblastic Neoplasia. International Journal of Gynecology and Obstetrics, 2006, 95, S193-S203.	2.3	28
76	Carcinoma of the Cervix Uteri. International Journal of Gynecology and Obstetrics, 2006, 95, S43-103.	2.3	503
77	Systemic therapy for gynecological neoplasms: Ovary, cervix and endometrium. Update on Cancer Therapeutics, 2006, 1, 515-538.	0.4	2
78	A Clinical Outcome-Based Prospective Study on Venous Thromboembolism After Cancer Surgery. Annals of Surgery, 2006, 243, 89-95.	4.2	595
79	Correlation between serological immune response analyzed by a new ELISA for HPV-16/18 E7 oncoprotein and clinical characteristics of cervical cancer patients. Archives of Virology, 2006, 151, 1899-1916.	2.1	17
80	Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: Identification of novel molecular biomarkers for early diagnosis and therapy. Gynecologic Oncology, 2006, 103, 405-416.	1.4	104
81	Optimizing Gemcitabine Regimens in Ovarian Cancer. Seminars in Oncology, 2006, 33, 17-25.	2.2	12
82	Extending the Platinum-Free Interval with a Non-Platinum Therapy in Platinum-Sensitive Recurrent Ovarian Cancer. Oncology, 2006, 71, 320-326.	1.9	30
83	Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecologic Oncology, 2004, 95, 593-596.	1.4	222
84	Five-year follow-up of placental involution after abdominal pregnancy. Journal of Clinical Ultrasound, 2003, 31, 39-43.	0.8	15
85	Morphologic and biologic studies on ten cases of verrucous carcinoma of the vulva supporting the theory of a discrete clinico-pathologic entity. International Journal of Gynecological Cancer, 2003, 13, 317-324.	2.5	46
86	Consolidation therapies revisited: weekly paclitaxel. International Journal of Gynecological Cancer, 2003, 13, 208-211.	2.5	12
87	Cancer in women. International Journal of Gynecology and Obstetrics, 2003, 82, 369-379.	2.3	84
88	Carcinoma of the vulva. International Journal of Gynecology and Obstetrics, 2003, 83, 7-26.	2.3	13
89	Carcinoma of the vagina. International Journal of Gynecology and Obstetrics, 2003, 83, 27-39.	2.3	26
90	Carcinoma of the corpus uteri. International Journal of Gynecology and Obstetrics, 2003, 83, 79-118.	2.3	187

#	ARTICLE	IF	CITATIONS
91	Carcinoma of the fallopian tube. International Journal of Gynecology and Obstetrics, 2003, 83, 119-133.	2.3	16
92	Gestational trophoblastic diseases. International Journal of Gynecology and Obstetrics, 2003, 83, 167-174.	2.3	5
93	Carcinoma of the cervix uteri. International Journal of Gynecology and Obstetrics, 2003, 83, 41-78.	2.3	160
94	Cervical Cancer Staging. Cancer Journal (Sudbury, Mass), 2003, 9, 390-394.	2.0	45
95	Interval debulking surgery in advanced epithelial ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 573-583.	2.8	19
96	STAGING OF GYNECOLOGIC MALIGNANCIES. Surgical Clinics of North America, 2001, 81, 753-770.	1.5	5
97	Early stage ovarian cancer: the Italian contribution to clinical research. An update. International Journal of Gynecological Cancer, 2001, 11, 12-19.	2.5	14
98	Ovarial cancer: best timing and applications of debulking surgery. Annals of Oncology, 2000, 11, 141-144.	1.2	4
99	Title is missing!. Annals of Oncology, 2000, 11, 141-144.	1.2	9
100	Replacement therapy for breast cancer survivors. A pilot study. Cancer, 1995, 76, 2075-2078.	4.1	29
101	Replacement therapy for breast cancer survivors. A pilot study. Cancer, 1995, 76, 2075-2078.	4.1	1
102	The treatment of progressive ovarian carcinoma with D-Trp-LHRH (decapeptyl). European Journal of Cancer, 1994, 30, 1903-1904.	2.8	11
103	High-Risk Early-Stage Ovarian Cancer Randomized Clinical Trial Comparing Cisplatin Plus Cyclophosphamide versus Whole Abdominal Radiotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 72-76.	1.3	60
104	Randomized Study Comparing Chemotherapy Plus Radiotherapy Versus Radiotherapy Alone in FIGO Stage IIB-III Cervical Carcinoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 1994, 17, 294-297.	1.3	56
105	Recurrent ovarian carcinoma: Salvage treatment with platinum in patients responding to first-line platinum-based regimens. European Journal of Cancer, 1993, 29, 652.	2.8	1
106	Hormone replacement therapy In breast cancer. Lancet, The, 1993, 342, 1232.	13.7	61
107	Adjuvant cisplatin-based chemotherapy for stage I and II ovarian cancer: a 7-year experience. European Journal of Cancer & Clinical Oncology, 1991, 27, 1211-1215.	0.7	7
108	Crossover study with cisplatin or carboplatin in advanced ovarian cancer. Gynecologic Oncology, 1990, 39, 146-149.	1.4	10